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Abstract  
Conjugated linoleic acid (CLA) is a family of 28 positional and geometrical isomers of 
linoleic acid (LA), found predominantly in the meat of ruminant animals. The health 
benefits of CLA have been widely researched, with specific interest into its anti-obesity 
and anti-carcinogenic properties. Conclusions from in-vivo studies have suggested that, 
with further research, CLA supplementation may be used in conjunction with current 
treatments for breast cancer and rectal cancer. In-vitro research into the anti-
carcinogenic effects of CLA has revealed that different CLA isomers affect cancer cells 
through several different pathways. The anti-proliferative effects of cis-9, trans-11 CLA 
and trans-10, cis-12 CLA have been demonstrated in-vitro, specifically on colon cancer, 
breast cancer, and prostate cancer. Ultimately, it has been concluded that the anti-
proliferative effects of CLA isomers are dependent upon the type and malignancy of 
the cancer cells targeted. After reviewing the literature, it is clear that there is a gap in 
the research. To our knowledge, no study has ever tested the effects of CLA on the 
proliferation of epidermoid carcinoma cells, specifically the cis-9, trans-11 CLA isomer. 
This research could add to the growing body of evidence surrounding the effects of 
specific CLA isomers on different types of cancer in-vitro. 
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Conjugated linoleic acid (CLA) is a collective term for 28 positional and geometrical 
isomers of linoleic acid (LA), found primarily in the meat of ruminant animals (Koba & 
Yanagita, 2014). CLA is an 18-carbon polyunsaturated fatty acid, with double bonds at 
positions 8 and 10, 9 and 11, 10 and 12 or 11 and 13, each occurring in a cis-trans, 
trans-cis, cis-cis, or trans-trans configuration (Evans, Brown & McIntosh, 2002) (see 
Figure 1). The double bonds of CLA are separated by a single bond, providing the name 
‘conjugated’ (Evans et al., 2002). CLA is synthesised in the gut of ruminant animals 
through the incomplete bio-hydrogenation of LA (Silva, 2014). Naturally occurring CLA 
predominantly consists of the cis-9, trans-11 isomer, also known as rumenic acid 
(Kramer et al., 1998). The principle dietary sources of CLA are beef and lamb, and 
ruminant dairy products, such as milk, butter and yoghurt (Chin, Liu, Storkson, Ha, & 
Pariza, 1992). Over the past three decades, CLA has gained significant scientific 
attention, after its anti-cancer (Ha, Grimm, & Pariza, 1987) and anti-obesity (Park et al., 
1997) properties were discovered (Kim, Kim, Kim, & Park, 2016). According to Koba 
and Yanagita (2014) and Kim et al. (2016), recent reviews suggest that the 
physiological effects of CLA depend on its constituent isomers, with the trans-10, cis-
12 isomer showing anti-carcinogenic, anti-obesity and anti-diabetic properties (Park, 
Storkson, Albright, Liu & Pariza, 1999) and the cis-9, trans-11 isomer predominantly 
anti-carcinogenic (McGowan et al., 2013; Mohammadzadeh, Faramarzi, Mahdahvi, 
Nasirimotlagh & Jafarabadi, 2013). However, much of the evidence surrounding the 
health benefits of CLA has been gathered from animal studies, with very little research 
conducted in-vivo with human subjects (Bhattacharya, Banu, Rahman, Causey & 
Fernandes, 2006). CLA has also been shown to decrease proliferation and increase 
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apoptosis of certain cancer cells in-vitro, including colon cancer (Beppu et al., 2006), 
liver cancer (Igarashi & Miyazawa, 2000), and breast cancer (Shultz, Chew & Seaman, 
1992) cells.  
 
 
 
 
 
 
 
Figure 1. The structure of linoleic acid compared to the two main isomers of 
CLA, cis-9, trans-11 CLA and trans-10, cis-12 CLA (Evans et al., 2002).  
 
Synthesis of Conjugated Linoleic Acid in the Rumen  
Kepler, Hirons, McNeill and Tove (1966) found that cis-9, trans-11 CLA was 
derived from the incomplete bio-hydrogenation of polyunsaturated LA to saturated 
stearic acid in the gut of ruminant animals. This chemical process was found to be 
carried out by bacteria, known as Butyrivibrio fibrisolvens, and is responsible for the 
vast majority of CLA production (Kepler et al., 1966). Chin, Storkson, Liu, Albright, and 
Pariza (1994) state that a small amount of cis-9, trans-11 CLA is absorbed directly into 
surrounding tissue, whereas most is hydrogenated at the 9-position in order to yield 
vaccenic acid (Harfoot & Hazlewood, 1988). The cis-9, trans-11 isomer can be 
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synthesised from vaccenic acid by the action of the Δ9-desaturase enzyme in the 
mammary and adipose cells of ruminants (Lawson, Moss & Givens, 2001).  
 
Isomers of Conjugated Linoleic Acid 
Although cis-9, trans-11 CLA is the predominant isomer found in natural 
sources, it is not the only important isomer, as trans-10, cis-12 is found in CLA that has 
been manufactured from LA (Kim et al., 2016). CLA isomers can be synthesised in the 
laboratory from LA, or oils high in LA, such as sunflower, safflower, and soybean (Sehat 
et al., 1998).  Synthetic CLA isomers consist of 40-41% cis-9, trans-11, 44-45% trans-10, 
cis-12, and 5-10% trans-trans isomers (Silva, 2014). This preparation of CLA is often 
termed CLA mixture, or CLA 50:50 (Kim et al., 2016). Naturally occurring CLA is present 
at very low concentrations, and therefore CLA mixture is used for most research 
purposes (Kim et al., 2016). Both cis-9, trans-11 CLA and trans-10, cis-12 CLA have 
different biological roles (Bhattacharya et al., 2006), and the less common trans-trans 
isomers have been found to exhibit anti-cancer (Beppu et al., 2006), anti-inflammation 
(Lee, Lim, Park & Kim, 2009) and hypocholesterolaemic (Gilbert, Gadang, Proctor, Jain 
& Devareddy, 2011) properties.  
 
Dietary Sources of Conjugated Linoleic Acid 
Research from Chin, Storkson and Pariza (1993) showed that the cis-9, trans-11 
CLA isomer accounted for 73-94% total CLA in milk, dairy products, meat and 
processed meat. CLA content of meat can range from 5.6mg/g fat in lamb to 2.7mg/g 
fat in veal, with concentrations much lower in seafood (>0.6mg/g fat) and plant oils 
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(>0.7mg/g fat) (Chin et al., 1992).  Mushtaq, Mangiapane and Hunter (2010) 
determined the CLA content of 112 UK food stuffs and found that processed cheese 
slices contained the highest concentration of cis-9, trans-11 CLA, at 7.3mg/g fat. It was 
suggested that the high CLA content of processed cheese slices was due to heat 
treatment during the food manufacturing process, and the addition of whey protein, 
which has been shown to increase CLA content in cheese (Shantha, Decker & Ustunol, 
1992).   
Dietary intake of CLA can vary, depending on individual diets, food processing, 
and cattle feeding (Chin et al., 1992). Mushtaq et al. (2010) estimate that dietary 
intake of CLA from natural sources in the UK is 97.5 mg/d, compared with the 
estimated 200 mg/d for men and 93-151 mg/d for women in the USA (Herbel, 
McGuire, McGuire & Shultz, 1998).  
 
Anti-Obesity Effects of Conjugated Linoleic Acid 
Arguably, the focus of CLA in scientific research has been its anti-obesity effects 
(Kim et al., 2016). Meta-analyses of human clinical studies have concluded that CLA 
supplementation has led to improvements in body mass index (BMI) and abdominal 
adiposity, when supplemented at 3.2-3.4g/d for at least 6 months (Whigham, Watras 
& Schoeller, 2007; Schoeller, Watras & Whigham, 2009). However, a meta-analysis 
from Onakpoya, Posadzki, Watson, Davies and Ernst (2012) concluded that evidence 
from randomised controlled trials was not enough to convincingly show that CLA had 
any effects on body composition in the long-term. It should also be noted that in-vivo 
human studies are rare, and the strongest evidence linking CLA to its anti-obesity 
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effects is from animal studies, specifically mice and rats (Bhattacharya et al., 2006). 
Park et al. (1997) tested the effects of CLA on body composition in mice and found that 
those fed a CLA-supplemented diet exhibited 60% less body fat than those fed a 
controlled diet. It is believed that the mechanisms behind CLA and anti-obesity in 
animals involves an increase in energy expenditure and fat utilisation, and a decrease 
in lipid storage, lipid synthesis, and adipogenesis in adipocytes (Park & Pariza, 2007; 
Park et al., 1997). It is specifically trans-10, cis-12 CLA that has been linked to 
improvements in body composition, whereas cis-9, trans-11 CLA has been shown to 
have no effects (Park et al., 1999).  
 
Anti-Carcinogenic Effects of Conjugated Linoleic Acid 
In addition to CLA’s proposed anti-obesity health benefits, there has also been 
evidence linking CLA with the treatment and prevention of cancer (Kim et al., 2016). As 
with the anti-obesity research, most of the evidence gathered in this area is from 
animal-based studies. Ha et al. (1987) tested the effects of CLA on mice, and found 
that those treated with CLA had 50% less tumour incidence than those treated with 
pure LA. More recently, a small amount of human studies have investigated the effects 
of CLA intake on tissue CLA and cancer incidences, yet the findings were inconsistent 
(Bhattacharya et al., 2006). There are even fewer clinical trials involving the 
administration of CLA to cancer patients (Kim et al., 2016). A clinical trial conducted by 
McGowan et al. (2013) investigated the effects of CLA on the proliferation of breast 
cancer tumours. It was hypothesised that the administration of CLA would inhibit the 
expression of markers related to fatty acid synthesis in tumour tissue, and thus aid the 
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suppression of tumour proliferation. McGowan et al. (2013) provided 7.5g/d CLA 
mixture to 24 women with Stage I-III breast cancer, at least 10 days before their 
surgery. Using an immunohistochemical staining scoring system, it was shown that 
there was a significant decrease (p=.003) in the expression of Spot 14 (S14), a breast 
cancer tumour proliferation marker associated with lipid metabolism. In 11 of the 13 
women with the most advanced tumours, and with the highest immunohistochemical 
staining scores, the supplementation of CLA was shown to decrease S14 expression, 
and thus lower their staining scores. In patients with less advanced tumours, and a 
lower staining score, CLA was found to have no effect on S14 expression. Therefore, it 
was suggested that CLA supplementation was more effective in the later stages of 
cancer when considering S14 expression. McGowan et al. (2013) propose that this 
score decrease suggests that the initial metabolic status of breast cancer cells may 
affect their response to CLA supplementation. Based on their observations, it was 
concluded that CLA may be used in conjunction with current breast cancer treatments.  
A clinical trial from Mohammadzadeh et al. (2013) investigated the effects of 
CLA on rectal cancer patients undergoing chemoradiotherapy (CRT) in Tabriz, Iran. The 
experiment was a randomised, double-blind, placebo-controlled trial with 32 
participants (18 male and 14 female). Participants were hospital patients with either 
stage II (n=12) or stage III (n=20) rectal cancer. Patients were given 3g/d of either CLA 
mixture (containing equal quantities of cis-9, trans-11 CLA and trans-10, cis-12 CLA) or 
placebo sunflower oil capsules, to take every day for six weeks. Results revealed that in 
comparison to the placebo group, patients consuming CLA had significantly improved 
biomarkers of inflammation (p=.004) and of angiogenesis and tumour invasion 
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(p=.004), indicated by levels of tumour necrosis factor α (TNF-α) and matrix 
metalloproteinase-2 (MP-2) enzyme, respectively. Angiogenesis is the growth of new 
blood vessels, allowing tumour growth through the deliverance of nutrients 
(Murukesh, Dive & Jayson, 2010). Angiogenesis biomarker discoveries can aid the 
treatment of rectal cancer, as they allow for the identification of cancer cells, and 
therefore the use of angiogenesis inhibitors (Mousa, Salem & Mikhail, 2015). 
Mohammadzadeh et al. (2013) concluded that CLA supplementation may provide 
complimentary treatment by reducing tumour invasion, and resistance to cancer 
treatment, in rectal cancer patients. 
 
Conjugated Linoleic Acid In-vitro 
CLA has been used for in-vitro studies using immortal cancer cell lines (Kim et 
al., 2016). Immortalised cell lines are developed from a single cell and have a uniform 
genetic makeup (Holliday & Speirs, 2011). They proliferate indefinitely, and are 
therefore cultured for many different types of in-vitro research. There is a body of 
research focusing on the in-vitro effects of CLA on a multitude of cancer cell lines, 
including colon cancer, breast cancer, and prostate cancer (Bhattacharya et al., 2006).  
Results all seem to be in agreement, and conclude that CLA either slows cancer cell 
proliferation (growth), or induces cell apoptosis (death) (Schønberg & Krokan, 1995). 
However, the evidence surrounding the effects of individual isomers on cancer cell 
proliferation is inconclusive (Maggiora et al., 2004). Shahzad et al. (2018) suggest that 
the effects of the different isomers, and their anti-proliferation mechanisms, are likely 
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to depend on the type and genetic makeup of the cancer cells themselves. Therefore, 
each cancer cell line may be affected differently with each isomer.  
Palombo, Ganguly, Bistrian and Menard (2002) tested the effects of two 
commercial preparations of CLA, and three individual CLA isomers, on the proliferation 
of human colorectal (HT-29 and MIP-101) and prostate (PC-3) carcinoma cells. Each 
CLA preparation contained different major isomers, in varying proportions, with the 
first preparation (CLA-PN) consisting of 35% cis-9, trans-11 CLA and 36% trans-10, cis-
12 CLA, and the second preparation (CLA-MAT) consisting of 75% cis-9, trans-11 CLA, 
19% cis-9, cis-11 CLA and 1% trans-9, trans-11 CLA. Each of these two preparations of 
CLA were tested on HT-29, MIP-101, and PC-3 in concentrations of 178μM, 100μM, 
and 36μM. Palombo et al. (2002) also tested the effects of the cis-9, trans-11 CLA, cis-
9, cis-11 CLA, and trans-10, cis-12 CLA individual isomers on the proliferation of HT-29, 
MIP-101, and PC-3, in concentrations of 100μM and 50μM.  
HT-29 proliferation was completely inhibited (100%) by both CLA preparations 
at 178μM and 100μM, with a 50% inhibition at 36μM (p<.001). MIP-101 proliferation 
was inhibited by CLA-PN in a dose dependent manner at 178μM (p<.001), 100μM 
(p<.001) and 36μM (p<.005). However, CLA-MAT only significantly reduced MIP-101 
cell proliferation at 178μM (p<.001), with no observed effects at either 100μM or 
36μM. PC-3 proliferation was significantly inhibited by both CLA-PN (p<.001) and CLA-
MAT (p<.001) at 178μM only, with no observed effects at 100μM or 36μM. CLA-PN 
was least effective at decreasing PC-3 cell proliferation (53%) when compared to HT-29 
(100%) and MIP-101 (83%).  
J45359     Conjugated Linoleic Acid and Cancer 
 
 
18 
 
All individual isomers were significantly effective at reducing the proliferation 
of HT-29 cells at 100μM (p<.001) when compared with control groups, with 95% 
inhibition from cis-9, trans-11 CLA and trans-10, cis-12 CLA, and 80% inhibition from 
cis-9, cis-11 CLA. Both cis-9, trans-11 CLA and trans-10, cis-12 CLA significantly reduced 
proliferation by 50% at 50μM (p<.001). However, there were no observed effects on 
proliferation from cis-9, cis-11 CLA on the HT-29 cells. Both cis-9, cis-11 CLA and cis-9, 
trans-11 CLA were significantly effective (p<.001) at reducing MIP-101 cell 
proliferation, albeit to a lesser extent than trans-10, cis-12 CLA at both 100μM (95% 
reduction) and 50μM (80% reduction) (p<.001). PC-3 cell proliferation was significantly 
reduced by all isomers at 100μM (p<.001), yet not at 50μM, relative to the control 
group. The reduced proliferation of PC-3 cells by cis-9, trans-11 CLA was relatively low 
(32%) when compared with HT-29 (95%) and MIP-101 (49%) cells.  
The results suggest that trans-10, cis-12 CLA exhibits the highest anti-
proliferative effect on these cancer cell types, as it was found to be the most effective 
as an individual isomer, and as a main component of CLA-PN. Palombo et al. (2002) 
concluded that each of the cancer cells were affected in a dose- and isomer-dependent 
manner. The trans-cis and cis-trans CLA isomers were more effective at reducing, or 
completely inhibiting, cell proliferation than the cis-cis isomer. It was also concluded 
that net reduction in cancer cells is dependent upon the type and concentration of 
CLA, and the type of cancer cells targeted.  
More recent studies support the findings of Palombo et al. (2002) and illustrate 
the varying effects of different CLA isomers. Shahzad et al. (2018) studied the effects of 
trans-10, cis-12 CLA and cis-9, trans-11 CLA on the proliferation, migration, and 
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invasion of two different ovarian cancer cell lines, SKOV-3 and A2780. SKOV-3 and 
A2780 were plated in 96-well culture plates and treated with either trans-10, cis-12 
CLA or cis-9, trans-11 CLA over four time points: 24 hours, 48 hours, 72 hours, and 96 
hours. Trans-10, cis-12 CLA and cis-9, trans-11 CLA were added to the ovarian cancer 
cells in seven different concentrations: 0μM, 1μM, 5μM, 10μM, 15μM, 20μM and 
25μM. Results showed that all concentrations of cis-9, trans-11 CLA had no observed 
effect on the proliferation or viability of SKOV-3 and A2780 cells. On the contrary, 
trans-10, cis-12 CLA significantly (p<.001) reduced the proliferation of both SKOV-3 
(90%) and A2780 (60%) cells. Results also showed that both cis-9, trans-11 CLA and 
trans-10, cis-12 CLA had no effect on apoptosis in either cell line. Shahzad et al. (2018) 
concluded that trans-10, cis-12 CLA should be considered for the treatment of ovarian 
cancer. 
 Beppu et al. (2006) tested different isomers of CLA on three colon cancer cell 
lines, CaCo-2, HT-29, and DLD-1. The cultured cells were treated with trans-9, trans-11 
CLA, cis-10, trans-12 CLA, cis-9, trans-11 CLA, and cis-9, cis-11 CLA, in concentrations 
ranging from 50μM to 200μM. The treated cells were incubated for 24 hours, 48 hours, 
and 72 hours, and tested for viability using an absorbance reader. The viability of the 
CaCo-2 cells was most strongly affected by the trans-9, trans-11 CLA isomer, which 
when compared to the control cells, reduced cell viability by 68% at 24 hours, 90% at 
48 hours, and 98% at 72 hours. In comparison, the cis-9, trans-11 CLA isomer reduced 
cell viability by 20% at 24 hours, 35% at 48 hours, and 45% at 72 hours, when 
compared to the viability of control cells. Trans-9, trans-11 CLA was found to be most 
effective at reducing cell viability at a concentration of 200μM, however cell viability 
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was also reduced (<20%) with concentrations of 100μM and 50μM. The viability of the 
HT-29 and DLD cells was significantly reduced (p<.001) by the trans-9, trans-11 isomer 
only, with HT-29 at 58% of control cells and DLD at 68%. These findings conflict the 
evidence of Palombo et al. (2002), who found that HT-29 cell growth was inhibited up 
to 95% by cis-9, trans-11 CLA and up to 80% by cis-9, cis-11 CLA. Beppu et al. (2006) 
found that trans-9, trans-11 CLA significantly induced apoptosis (p<.001) in the CaCo-2 
cells at concentrations of 50μM, 100μM and 200μM. Beppu et al. (2006) concluded 
that all CLA isomers acted in a dose- and time-dependent manner, with the trans-9, 
trans-11 CLA isomer showing the strongest anti-carcinogenic activity, yet state that the 
exact mechanism behind its actions is unknown. Proposed mechanisms involve 
increased lipid peroxidation, alteration of cellular fatty acid composition, and 
regulation of certain gene expressions (Beppu et al., 2006).  
Despite there being evidence that trans-10, cis-12 CLA and trans-9, trans-11 
CLA isomers have the most potent anti-proliferative effects (Shahzad et al., 2018; 
Palombo et al., 2002; Beppu et al., 2006), there is also evidence supporting the anti-
carcinogenic properties of cis-9, trans-11 CLA. Liu et al. (2002) treated mammary 
cancer (MCF-7) in-vitro with 25µM, 50µM, 100µM and 200µM cis-9, trans-11 CLA for 
24 hours and 48 hours. After 48 hours, cell growth was inhibited by 27% at 25µM, 35% 
at 50µM, 91% at 100µM, and 93% at 200µM. It was suggested by Liu et al. (2002) that 
the actions of cis-9, trans-11 CLA involved the cell cycle arrest of MCF-7. The 
mechanism behind the action was further investigated by Liu et al. (2002), who tested 
cis-9, trans-11 CLA on gastric adenocarcioma cells (SGC-7901), in concentrations of 
25μM, 50μM, 100μM, and 200μM, for 24 hours and 48 hours. After 48 hours, cell 
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growth rates were inhibited by 6% at 25μM, 20% at 50μM, 76% at 100μM, and 82% at 
200μM. There was also a significantly greater incidence of apoptosis at all 
concentrations when compared to control cells (p<.01). From their results investigating 
biomarkers of proliferation (Ki67) and apoptosis (Bcl-2), and apoptosis antigens (Fas) 
and genes (c-myc), Liu et al. (2002) concluded that cis-9, trans-11 CLA blocked the cell-
cycle at the G0/G1 phase. CLA treated cells expressed significantly less Ki67 than 
control cells (p<.01), in a dose-dependent manner. However, Liu et al. (2002) state that 
the exact mechanisms behind the action of cis-9, trans-11 CLA are not fully 
understood, and require more research.  
 
Proposed mechanisms behind CLA effects 
Cho et al. (2003) found that CLA mixture inhibited both cell proliferation, DNA 
synthesis, and ErbB3 signalling in HT-29 human colon cancer cells. ErbB3 is part of a 
family of epidermal growth factor receptors (EGFR), which are involved in several 
processes, including cell proliferation and cell differentiation (Nicholson, Gee & 
Harper, 2001). Over expression of one receptor, ErbB2, has been linked with ErbB3 and 
the development of colon cancer, with both proteins expressed in the HT-29 cell line at 
high levels (Cho et al., 2003). The mechanisms behind the CLA regulation of ErbB2 and 
ErbB3 were not investigated by Cho et al. (2003), yet it has been suggested that CLA 
alters gene transcription by acting as a ligand for PPARγ. Ligands for PPARγ have been 
found to induce cell apoptosis and have anti-proliferative effects on many carcinoma 
cell lines (Elstner et al., 1998; Kwon, Jovanovic, Serfas, Kiyokawa & Tyner, 2002).  
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The A431 epidermoid carcinoma cell line  
 Epidermoid carcinoma, also known as squamous cell carcinoma, is one of the 
largest sub-sets of cancer (Berman, 2004). Epidermoid carcinoma is a type of cancer 
that affects the cells forming the surface of the skin, the lining of hollow organs, and 
the lining of the digestive and respiratory tracts (Melo Neto et al., 2013). Epidermoid 
carcinoma comprises several cancers, such as skin, lung, and vaginal, each associated 
with different symptoms, prognosis and response to treatment (Yu, Yang, Hu & Yan, 
2009). The A431 epidermoid carcinoma cell line originates from the vulva of an 85-year 
old female cancer patient (Barnes, 1982). A431 cells are commonly used in cancer 
studies due their high expression of epidermal growth factor receptors (EGFR) (Bhatia, 
Agarwal & Agarwal, 2001).  
 
Conclusion 
 The literature surrounding the health benefits of CLA is extensive. Although 
much of the original research was conducted using animal subjects, more recent 
studies have used human cells for in-vitro, and human patients for hospital-based 
clinical trials. Most of the evidence illustrates that CLA exhibits beneficial effects on 
human health. Findings from anti-obesity research have illustrated that 
supplementation with CLA leads to a short-term significant reduction in BMI, total 
body weight and abdominal adiposity. Evidence from clinical trials suggest that 
supplementation with CLA can lead to a reduction in tumour proliferation in women in 
the later stages of breast cancer. Further research has shown that when compared to 
placebo, CLA supplementation improves biomarkers of inflammation and tumour 
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invasion in rectal cancer patients in Iran. Extensive in-vitro research has focused on the 
anti-proliferative effects of commercial CLA preparations and individual CLA isomers 
on cancer cells. There is a large body of evidence illustrating the anti-proliferative 
effects of CLA on colon, prostate, breast and ovarian cancer. Certain studies highlight 
the effects of individual isomers, specifically trans-10, cis-12 CLA and cis-9, trans-11 
CLA, for their anti-proliferative properties. All studies thus far agree that the trans-10, 
cis-12 CLA isomer has the strongest anti-proliferative properties. However, regarding 
the cis-9, trans-11 CLA isomer, evidence is conflicting. Certain studies have found 
significant effects of cis-9, trans-11 CLA on the reduced proliferation of breast and 
gastric cancer cells. Moderate effects have been found from studies involving colon 
and prostate cancer, and no effects were found in ovarian cancer. However, most in-
vitro studies have concluded that the effects of individual CLA isomers are specific to 
the cancer cells that are being treated. All in-vitro studies show that CLA works in a 
dose- and time-dependent manner, yet the exact mechanisms behind the actions 
remain inconclusive, with theories proposing lipid peroxidation, alteration of cellular 
fatty acid composition, and regulation of certain gene expressions. 
 To date, in-vitro CLA research has focused on multiple cancer cell lines, 
including HT-29, MIP-101, PC-3, SKOV-3, A2780, CaCo-2, DLD-101, and MCF-7. To our 
knowledge, there are currently no studies that have tested the effects of CLA on the 
proliferation of A431 epidermoid carcinoma cells, specifically the cis-9, trans-11 CLA 
isomer. Some of the evidence surrounding the effects of this isomer is conflicting, 
however its anti-proliferative effects have been shown when tested on colon, prostate, 
and gastric cancer, with the strongest effects shown on breast cancer.   
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 The current study will test the effects of four different concentrations of cis-9, 
trans-11 CLA on the proliferation of A431 epidermoid carcinoma cells over 48 hours. 
Based on previous literature, it is hypothesised that cis-9, trans-11 CLA will slow the 
proliferation of A431 cells in a time- and dose-dependent manner.  
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Journal Style Justification  
The journal deemed suitable for this article is The Journal of Nutritional Biochemistry. 
The Journal of Nutritional Biochemistry is devoted to advancements in nutritional 
sciences, presenting experimental nutrition research in relation to biochemistry, 
molecular biology, toxicology, and physiology. This article links the area of nutrition 
with biochemistry and molecular biology, through the examination of the effects of 
conjugated linoleic acid on the proliferation of cultured A431 epidermoid carcinoma 
cells. 
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Abstract 
Background and aims  
The aim of this study was to investigate the effects of varying concentrations of the cis-
9, trans-11 isomer of conjugated linoleic acid (CLA) on the proliferation of A431 
epidermoid carcinoma cells across three separate time points. A strong collection of in-
vitro studies illustrate the anti-carcinogenic properties of CLA isomers on colon cancer, 
prostate cancer, breast cancer, and ovarian cancer. Currently, there is no research 
investigating the effects of CLA on the proliferation of epidermoid carcinoma, 
specifically the cis-9, trans-11 CLA isomer.  
 
Methods  
Four concentrations of cis-9, trans-11 CLA (25μM, 50μM, 100μM and 200μM) were 
tested on cultured A431 epidermoid carcinoma cells. Proliferation was measured using 
an MTS assay after zero hours, 24 hours, and 48 hours.  
 
Results 
All treated cells were found to significantly proliferate between zero and 24 hours. 
There were no significant differences in proliferation found between the treated cells 
and the control cells.  
 
Conclusion 
The findings of this study do not support previous in-vitro studies on the anti-
proliferative effects of cis-9, trans-11 CLA. In future, cells should be incubated with the 
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treatment for a longer period, in order to observe potentially anti-proliferative effects. 
However, as a result of the current findings, cis-9, trans-11 CLA should not be used as a 
treatment for, or in conjunction with treatment for, epidermoid carcinoma.  
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1. Introduction 
Conjugated linoleic acid (CLA), an isomer of linoleic acid (LA), is a naturally 
occurring 18-carbon polyunsaturated fatty acid found in the meat and dairy products 
of ruminant animals (Chin, Liu, Storkson, Ha & Pariza, 1992). There are 28 positional 
and geometrical isomers of CLA, with double bonds arranged in cis-trans, trans-cis, cis-
cis, or trans-trans configurations (Kepler, Hirons, McNeill & Tove, 1966). CLA is 
produced in the gastrointestinal tract of ruminant animals, by bacteria known as 
Butyrivibrio fibrosolvens, or is synthesised in ruminant mammary and adipose cells by 
the action of the Δ9-desaturase enzyme (Lawson, Moss & Givens, 2001).  
 The major isomer found in food is cis-9, trans-11 CLA, accounting for 73-94% of 
CLA found in dairy products and meat (Chin et al., 1992). Mushtaq, Mangiapane and 
Hunter (2010) estimated dietary intake of CLA to be 97.5mg/d in the UK.  
 Early research into the effects of CLA revealed its anti-carcinogenic properties 
(Ha, Grimm & Pariza, 1987), and positive effects on body composition (Park et al., 
1997). However, many of the original studies were conducted on mice and rats (Kim, 
Kim, Kim & Park, 2016). More recently, human in-vitro and in-vivo studies have 
supported the original findings and identified key isomers and the mechanisms behind 
their actions (Park et al., 1997). CLA has been shown to lead to an increase in cell 
apoptosis (death) and a slow in proliferation (growth), however the exact mechanisms 
are not fully understood (Kim et al., 2016). It has been proposed that the anti-
carcinogenic effects of CLA involve lipid peroxidation, alteration of fatty acid 
composition, and the regulation of gene expression (Beppu et al., 2006).  
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In-vivo studies have illustrated that CLA supplementation reduced tumour 
proliferation in females with late stage breast cancer (McGowan et al., 2013), and 
increased biomarkers of inflammation in rectal cancer patients (Mohammadezah, 
Faramarzi, Mahdahvi, Nasirimotlagh & Jafarabadi, 2013). Conclusions from these 
studies suggest that CLA should be used in conjunction with current cancer 
treatments. However, there are very few in-vivo studies investigating the anti-
carcinogenic effects of CLA, and most of the evidence is derived from in-vitro research.  
In-vitro studies have highlighted the anti-carcinogenic effects of the two main 
CLA isomers: cis-9, trans-11 and trans-10, cis-12. Strong anti-proliferative effects of cis-
9, trans-11 CLA have been found from studies focusing on breast cancer (Liu et al., 
2002) and gastric cancer (Liu et al., 2002), and moderate effects have been found in 
colon (Beppu et al., 2006; Palombo, Ganguly, Bristrian & Menard, 2002) and prostate 
cancer (Palombo et al., 2002). Shahzad et al. (2018) concluded from their investigation 
using ovarian cancer cells than cis-9, trans-11 CLA had no effect on cell proliferation for 
these specific cell lines. However, Palombo et al. (2002) state that the effects of the 
CLA isomers are dependent upon the type of cancer cells they are tested on. Findings 
from in-vitro studies show that cis-9, trans-11 CLA works in a time- and dose-
dependent manner in terms of anti-proliferative effects (Liu et al., 2002; Palombo et 
al., 2002).  
To date, in-vitro CLA research has focused on multiple cancer cell lines, 
including HT-29, MIP-101, PC-3, and MCF-7. To our knowledge, there are currently no 
studies that have investigated the effects of CLA on the A431 epidermoid carcinoma 
cell line. Epidermoid carcinoma is cancer of the cells that form the surface of the skin, 
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the lining of hollow organs, and the lining of the digestive and respiratory tracts (Melo 
Neto et al., 2013). Epidermoid carcinoma is one of the largest sub-sets of cancer, and 
includes skin cancer, lung cancer, and vaginal cancer (Berman, 2004). The A431 
epidermoid carcinoma cell line originates from the vulva of an 85-year old female 
cancer patient (Barnes, 1982). 
 The current study will test the effects of four different concentrations of cis-9, 
trans-11 CLA on the proliferation of A431 epidermoid carcinoma cells over 48 hours. 
Based on previous literature, it is hypothesised that cis-9, trans-11 CLA will slow the 
proliferation of A431 cells in a time- and dose-dependent manner. 
 
2. Methods and Materials 
2.1 Materials 
Epidermoid carcinoma cell line, A431, was purchased from the European 
Collection of Authenticated Cell Cultures (ECACC). The cis-9, trans-11 CLA isomer, and 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) colorimetric proliferation assay were purchased from Sigma Aldrich.  
 
2.2 Cell culture conditions 
 A431 cells were cultured in Dulbecco’s modified eagle medium (DMEM) 
(500ml) supplemented with 50ml (10%) foetal bovine serum (FBS) and 5ml (1%) 
penicillin, streptomycin and glutamine mixture. Cell cultures were maintained within 
an incubator at 37°C and 5% CO₂, and passaged when 80% confluent.   
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2.3 In-vitro CLA treatment 
Human epidermoid carcinoma cells were cultured and seeded at a density of 1 
x 10⁴ cells/well in 96-well microtiter plates. The cells were cultured in 100μL 
media/well and incubated for 24 hours at 37°C and 5% CO₂. Stock solutions of CLA 
were prepared in industrial methylated spirits (IMS) at a concentration of 200,000μM. 
A second stock was prepared in media from the IMS stock at a concentration of 
2,000μM, and diluted to the final concentrations of 25µM, 50µM, 100µM and 200μM. 
Each concentration was plated in triplicate. In addition, carrier control cells were also 
plated, containing cells and solvent, without cis-9, trans-11 CLA. Vehicle control cells 
were also plated, containing only media and MTS reagent in order to test the effects of 
the MTS reagent on the absorbance reading. Plates were incubated for the desired 
time period (0 hours, 24 hours or 48 hours), and 20μL/well MTS reagent was added 
directly onto the cells, and incubated for a further 2 hours. See Appendix A for full 
protocol.  
 
2.4 Cell proliferation assessment 
 Cell proliferation was assessed using colorimetric MTS 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. MTS 
tetrazolium compound reduction generated a coloured formazan product in viable 
cells, which was quantified by measuring absorbance at OD=490nm. Higher 
absorbance readings indicated viable cells, and therefore proliferation. 
 
2.5 Statistical Analysis 
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 Descriptive and inferential statistics were generated using Statistical Package 
for Social Scientists software (SPSS, Inc., version 24.0, Chicago, IL). A two-way mixed-
model analysis of variance (ANOVA) with Tukey post-hoc tests was conducted to 
examine the differences between the means of the between-subject variables 
(concentration of cis-9, trans-11 CLA) and the means of the within-subject variables 
(incubation time period). Homogeneity of variance was examined using Levene’s test. 
The significance level for all tests was set at p<.05. 
 
3. Results 
No significant interaction was found between the concentration of cis-9, trans-
11 CLA and incubation time on the proliferation of A431 epidermoid carcinoma cells 
(p=.06). Cell proliferation was significantly increased by time (p<.001). This difference 
was found to be between the zero hour and 24-hour plate readings (p<.001). Cell 
proliferation was found to significantly increase at 25μM from zero hours (M = .82 ± 
.03nm) to 24 hours (M = 1.13 ± .03nm, p = .001), at 50μM from zero hours (M = .88 ± 
.05nm) to 24 hours (M = 1.16 ± .06nm, p = .04), at 100μM from zero hours (M = .84 ± 
.06nm) to 24 hours (M = 1.19 ± .06nm, p = .004), at 200μM from zero hours (M = .90 ± 
.07nm) to 24 hours (M = 1.19 ± .05nm, p = .006), and control cells at zero hours (M = 
.82 ± .08nm) to 24 hours (M = 1.11 ± .09nm, p = .015). There were no significant 
differences at any concentration between the 24-hour and 48-hour plate readings 
(p=.21).  
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Cell proliferation was not significantly affected by concentration. Treating 
epidermoid carcinoma cells with cis-9, trans-11 CLA at a concentration of 25µM did not 
significantly affect proliferation when compared to controls (see Figure 1).  
 
 
 
 
 
 
 
 
Figure 1. The mean absorbance of control cells and cis-9, trans-11 CLA treated cells, at 
a concentration of 25µM, across three time points. Error bars represent ± SE. The 
asterisk indicates a significant increase in proliferation between 0 hours and 24 hours 
(* = p ≤.05, **= p≤.01). 
 
There were no significant differences found between the absorbance of cells 
treated with 25µM cis-9, trans-11 CLA and control cells at zero hours (p = 1.00) or 24 
hours (p = .99). At 48 hours, the absorbance of cells treated with 25µM cis-9, trans-11 
CLA (M = 1.19 ± .06nm) was not significantly different to the absorbance of control 
cells (M = 1.22 ± .06nm, p = .88).   
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Treating A431 epidermoid carcinoma cells with cis-9, trans-11 CLA at a 
concentration of 50µM did not significantly increase or decrease proliferation when 
compared to controls (see Figure 2).  
 
Figure 2. The mean absorbance of control cells and cis-9, trans-11 CLA treated cells, at 
a concentration of 50µM, across three time points. Error bars represent ± SE. The 
asterisk indicates a significant increase in proliferation between 0 hours and 24 hours 
(* = p ≤.05). 
 
There were no significant differences between the absorbance of cells treated 
with 50µM cis-9, trans-11 CLA and control cells at zero hours (p = .71) or 24 hours (p = 
.88). At 48 hours, the absorbance of cells treated with 50µM cis-9, trans-11 CLA (M = 
1.15 ± .03nm) was not significantly different to the control cells (M = 1.22 ± .06nm, p = 
.53).   
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Treating A431 epidermoid carcinoma cells with cis-9, trans-11 CLA at a 
concentration of 100µM did not significantly increase or decrease proliferation when 
compared to controls (see Figure 3).  
 
Figure 3. The mean absorbance of control cells and cis-9, trans-11 CLA treated cells, at 
a concentration of 100µM, across three time points. Error bars represent ± SE. The 
asterisk indicates a significant increase in proliferation between 0 hours and 24 hours 
(* = p ≤.05, **= p≤.01). 
 
There were no significant differences between the absorbance of cells treated 
with 100µM cis-9, trans-11 CLA and control cells at zero hours (p = .98) or 24 hours (p = 
.57). At 48 hours, the absorbance of cells treated with 100µM cis-9, trans-11 CLA (M = 
1.17 ± .04nm) was not significantly different to the control cells (M = 1.22 ± .06nm, p = 
.73).   
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Treating A431 epidermoid carcinoma cells with cis-9, trans-11 CLA at a 
concentration of 200µM did not significantly increase or decrease proliferation when 
compared to controls (see Figure 4).  
 
Figure 4. The mean absorbance of control cells and cis-9, trans-11 CLA treated cells, at 
a concentration of 200µM, across three time points. Error bars represent ± SE. The 
asterisk indicates a significant increase in proliferation between 0 hours and 24 hours 
(* = p ≤.05, **= p≤.01). 
 
There were no significant differences between the absorbance of cells treated 
with 200µM cis-9, trans-11 CLA and control cells at zero hours (p = .53) or 24 hours (p = 
.55). At 48 hours, the absorbance of cells treated with 200µM cis-9, trans-11 CLA (M = 
1.19 ± .06nm) was not significantly different to control cells (M = 1.22 ± .06nm, p = 
.84).   
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 When comparing each concentration across each time point, proliferation of 
the treated cells was found to slow in comparison to control cells (see Figure 5). 
However, no significant differences were found.  
 
Figure 5. The overall trend in proliferation of the five concentrations of cis-9, trans-11 
CLA across three time points.  
 
4. Discussion 
 The results from this experiment reject the hypothesis that cis-9, trans-11 CLA 
would inhibit the proliferation of A431 epidermoid carcinoma cells in a time- and dose-
dependent manner. There were no significant differences in proliferation found 
between control cells and any concentrations of cis-9, trans-11 CLA at any time point. 
Contrary to the hypothesis, results showed that time, independent of 
concentration, lead to a significant increase in cell proliferation. The absorbance 
measured at 24 hours was significantly higher than absorbance measured at zero 
hours across all concentrations and control cells. The absorbance measured at 48 
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hours was not significantly different to the absorbance measured at 24 hours. Results 
show that concentration had no significant effect on the proliferation of epidermoid 
carcinoma cells. Growth was expected to slow with the addition of cis-9, trans-11 CLA, 
especially with the higher concentrations of 100µM and 200µM. Control cells were 
predicted to grow as normal and show the highest rate of proliferation. However, the 
evidence supported neither of these predictions. 
There are currently no studies investigating the effects of cis-9, trans-11 CLA on 
the proliferation of epidermoid carcinoma cells, and the literature surrounding the in-
vitro effects of cis-9, trans-11 CLA is conflicting, with evidence both supporting and 
refuting its anti-carcinogenic properties (Bhattacharya, Banu, Rahman, Causey & 
Fernandes, 2006). When tested alone, cis-9, trans-11 CLA has shown significant anti-
proliferative effects on cancer cells, as well as inducing apoptosis (Liu et al., 2002; 
Chujo et al., 2003). However, when tested in conjunction with other CLA isomers, cis-9, 
- trans-11 CLA has shown the least anti-carcinogenic effects (Palombo et al., 2002; 
Shahzad et al., 2018).  
The findings from this study are in line with findings from Shahzad et al. (2018), 
who tested the effects of different CLA isomers on the proliferation of ovarian cancer 
cells (SKOV-3 and A2780). Cells were treated with varying concentrations (0μM to 
25μM) of either trans-10, cis-12 or cis-9, trans-11 CLA, and incubated for 24 to 96 
hours. From their results, Shahzad et al. (2018) concluded that cis-9, trans-11 CLA had 
no effect on either proliferation or apoptosis of either type of ovarian cancer cells. 
However, the trans-10, cis-12 isomer was found to significantly reduce proliferation 
and cell viability in both cell types.  
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The findings from the present study contradict evidence from Liu et al. (2002), 
focusing on breast cancer, and Liu et al. (2002), focusing on gastric cancer. Results 
from Liu et al. (2002), who tested the effects of cis-9, trans-11 CLA on the proliferation 
of MCF-7, a breast cancer cell line, showed that cis-9, trans-11 CLA significantly 
reduced the proliferation of MCF-7 cells in a time- and dose-dependent manner. The 
cis-9, trans-11 CLA dosage (25μM, 50μM, 100μM and 200μM), and the incubation time 
(24 and 48 hours), were exactly the same in the study from Liu et al. (2002) as they are 
in the present study. Further research from Liu et al. (2002) focused on the effects of 
cis-9, trans-11 CLA on the in-vitro proliferation of gastric adenocarcinoma cells (SGC-
7901). Using the exact same dosage and incubation time as the present study, and of 
Liu et al. (2002), it was found that cis-9, trans-11 CLA significantly inhibited the growth 
of SGC-7901 cells in a time- and dose-dependent manner. This inhibition was found to 
be due not only to a slow in proliferation, but also an increase in apoptosis.  
 The findings from Liu et al. (2002) and Liu et al. (2002) are in line with those of 
Beppu et al. (2006) who tested different isomers of CLA on the proliferation of three 
colon cancer cells lines (CaCo-2, HT-29, and DLD-1). The cis-9, trans-11 CLA isomer was 
found to significantly decrease the proliferation of all three colon cancers in 
concentrations ranging from 50μM to 200μM, across incubation periods of 24, 48 and 
72 hours. Although all isomers showed significant anti-proliferative actions, the effects 
of cis-9, trans-11 CLA were overshadowed by the effects of trans-9, trans-11 CLA and 
cis-10, trans-12 CLA.  
 The fact that cis-9, trans-11 CLA showed significant effects in the studies from 
Liu et al. (2002), Liu et al. (2002) and Beppu et al. (2006), yet showed no effects in the 
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study from Shahzad et al. (2018), nor the present study, could suggest that perhaps cis-
9, trans-11 CLA is only effective in certain types of cancer. According to Palombo et al. 
(2002), the in-vitro proliferation of cancer cells is dependent upon the type and 
concentration of CLA, as the effectiveness of the different isomers are not equivalent, 
and function through different mechanisms. This idea is supported by Maggiora et al. 
(2004), who suggest that the difference in effects is dependent upon the chemical 
nature of the fatty acid, or on the malignancy of the tumour cells. This could explain 
the conflicting body of evidence surrounding cis-9, trans-11 CLA, and why significant 
anti-proliferative effects have been found in certain in-vitro studies (Liu et al., 2002; 
Beppu et al., 2006), yet not the present study.  
 Support for the anti-proliferative effects of other isomers was provided by 
Palombo et al. (2002), who tested the effects of cis-9, trans-11 CLA, cis-9, cis-11 CLA, 
and trans-10, cis-12 CLA on the growth of prostate cancer (PC-3) and two types of 
colon cancer (CaCo-2 and MIP-101) at varying concentrations and incubation times. 
Results showed that both the cis-9, trans-11 CLA and trans-10, cis-12 CLA isomers were 
effective at slowing the proliferation of both CaCo-2 and MIP-101. Although all isomers 
showed anti-proliferative effects on the PC-3 cells, the actions of the cis-9, trans-11 
CLA isomer were relatively low when compared to cis-9, cis-11 CLA and trans-10, cis-12 
CLA.  
In order to understand the potential anti-proliferative effects of cis-9, trans-11 
CLA, it is important to understand the mechanisms behind its actions. Liu et al (2002) 
suggest that the actions of cis-9, trans-11 CLA involve cell cycle arrest, and speculated 
that cis-9, trans-11 CLA blocks the cell-cycle at the G0/G1 phase. Ochoa et al. (2004) 
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linked the actions of cis-9, trans-11 CLA with two enzymes, 5-LOX and COX-2. These 
enzymes are involved in arachidonic acid metabolism, an important factor in 
oncogenesis and the progression of cancer (Ochoa et al., 2004). In their study, Ochoa 
et al. (2004) demonstrated that cis-9, trans-11 CLA lead to significant decreases in 5-
LOX and COX-2 expressions. Cho et al. (2003) suggest that CLA alters gene transcription 
by acting as a ligand for PPARγ. PPARγ ligands have been found to induce cell 
apoptosis and slow cell proliferation in-vitro (Elstner et al., 1998). Ochoa et al. (2004) 
suggest that the increased apoptosis associated with cis-9, trans-11 CLA is due to the 
increased expression of Bcl-2, an important anti-apoptotic oncogene product. 
However, it is clear from the literature that the exact mechanisms behind the action of 
cis-9, trans-11 CLA are not fully understood (Liu et al., 2002). The results from the 
present study indicate that these mechanisms were not used by cis-9, trans-11 CLA on 
the A431 cell line. 
The main limitation of this study is that the treated cells were only incubated 
for 48 hours. An additional 24 hours incubation time could have led to significant 
differences in proliferation, as found by Chujo et al. (2003). Chujo et al. (2003) found 
that cis-9, trans-11 CLA significantly reduced the proliferation of MCF-7 breast cancer 
cells, only after 72 hours incubation. Furthermore, Maggiora et al. (2004) found that 
the inhibition of liver cancer cell proliferation was affected only after 48 hours of 
exposure, regardless of concentration used.  
 Another potential limitation of this study is that only one plate of cells was 
tested at each time point, providing only three readings for each concentration. These 
three readings may not have been accurate, and therefore could have affected results. 
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Although the present study is associated with some limitations, it should be 
remembered that this research was novel, and results add to the growing body of 
evidence showing that perhaps the cis-9, trans-11 CLA isomer may not be as anti-
carcinogenic as previously thought (Shahzad et al., 2018). 
 Research into the use of CLA as an alternative treatment for cancer is growing, 
however findings are inconclusive as to the effects of different isomers (Ochoa et al., 
2004). Results from in-vivo studies have led to the conclusion that CLA should be used 
in conjunction with current treatments for breast and rectal cancer (McGowan et al., 
2013; Mohammadzadeh et al., 2013). However, if CLA is to be used in the treatment of 
cancer, its mechanisms must first be fully understood (Kim et al., 2016). In terms of the 
cis-9, trans-11 CLA isomer, there is currently no evidence to suggest any anti-
proliferative effect on epidermoid carcinoma cells. Therefore, results from this study 
suggest that supplementation with cis-9, trans-11 CLA would not be an appropriate 
treatment for people suffering from epidermoid carcinoma. 
Future studies in this area may benefit from focusing on the effects of the 
trans-10, cis-12 CLA isomer. This isomer has shown strong anti-proliferative effects in 
the treatment of colon, prostate and ovarian cancers (Palombo et al., 2002; Shahzad et 
al., 2018). Based on this past research, trans-10, cis-12 CLA may prove effective at 
slowing the proliferation of A431 cells. Any future research using the cis-9, trans-11 
CLA on epidermoid carcinoma cells should consider a longer incubation time, as effects 
may only been seen after 72 hours (Chujo et al., 2003). Testing repeat plates may also 
give more valid results (Ibrahim et al., 2012).   
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 In conclusion, cis-9, trans-11 CLA may be regarded as an anti-carcinogenic 
component of the diet, effectively reducing the proliferation of colon, breast and 
gastric cancer in-vitro (Palombo et al., 2002; Liu et al., 2002; Liu et al., 2002). However, 
in the case of epidermoid carcinoma cells, this particular isomer has shown no 
significant anti-proliferative effects. Despite the facts that the results from this study 
reject the main hypothesis, the findings add to the growing body of research that 
disputes the anti-carcinogenic and anti-proliferative effects of cis-9, trans-11 CLA. In 
future, the use of tran-10, cis-12 CLA may potentially exhibit anti-proliferative effects 
on epidermoid carcinoma cells, based on previous extensive in-vitro evidence. 
However, current findings illustrate that the growth of A431 cells is not significantly 
affected by CLA, and therefore CLA should not be considered as a treatment for 
epidermoid carcinoma.  
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Appendix A 
 
Cell proliferation protocol 
 
  
MTS Assay Protocol  
 Calculate the amount of media needed  
 Remove media from fridge, aliquot calculated amount (8.4ml) and place in the 
water bath to warm up  
 Warm trypsin and PBS in water bath  
 Spray in media, waste bottle, pipettes, pipette tips, pipette tip waste bottle, a 
glass vial, and 4 x 96 well plates into the safety cabinet (spray in the whole packet 
of well plates and open within the hood).   
 Passage and count cells using haemocytometer (refer to passage protocol).  
 Calculations:  
o 10⁴ cells per well needed, and 21 wells per plate (4 plates, so 84 wells to
tal)  
o  (21 x 10⁴) x 4 = 84 x 10⁴ cells  
o (21 x 10⁴) x 4 = 8.4mL media  
 Divide 84 x 10 ⁴ by the amount of cells counted in the passage e.g. what 
we want/what we have. 
The answer is the amount of cells (in μL) that should be added to 8.4mL of media, 
to give 1 x 10⁴/100μL.  
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 Pipette the calculated amount of cells into the 8.4mL of media and mix  
 Add 100μL of the cell/media solution to each well of each plate (as 
per template) (4 plates; 21 wells each) using a single-tipped pipette.  
 Make sure to invert the tube every 2ml or so, to stop the cells settling (put the 
cap on first!)  
 Once all wells have been seeded, incubate the plates for 24 hours 
in the incubator at 37⁰C and 5% CO₂.  
Make the ethanol stock in preparation for the next day:  
o Remove the CLA from the freezer and allow to defrost  
o Spray CLA into the hood  
o Pipette 1mL of IMS (ethanol) into a glass vial  
o Pipette 6.2μL of CLA into the ethanol  
o Vortex for 2 minutes   
o Store overnight in a freezer at -20⁰C  
After 24 hours  
  Spray in waste bottle, pen, pipettes, pipette tips, pipette tip waste bottle, 4 
x 5ml bijous and ethanol stock.  
 Prepare the media stock solutions for each concentration:  
o Remove media from the fridge and spray into the cabinet  
o Aliquot 10mL of media and then warm in the water bath  
o Once warmed, spray back into the cabinet  
o Label 4 5ml bijou tubes “200mM”, “100mM”, “50mM” and “25mM”  
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o Pipette 1,980μL media into the tube labelled “200mM” 
(this should be done with two pipettes of 990μL)   
o Pipette 1,990μL media into the tube labelled “100mM” 
(this should be done with two pipettes of 995μL)  
o Pipette 1,995μL media into the tube labelled “50mM” 
(this should be done with two pipettes: one for 1,000μL and one for 995μL)  
o Pipette 1,997.5μL media into the tube labelled “25mM” 
(this should be done with three pipettes: one for 1000μL, one for 
995μL, and one for 2.5μL)  
  Add the ethanol stock into each of the 4 labelled tubes:  
o 200mM – pipette 20μL ethanol stock into the 1,980μL of media  
o 100mM – pipette 10μL ethanol stock into the 1,990μL of media  
o 50mM – pipette 5μL ethanol stock into the 1,995μL of media  
o 25mM – pipette 2.5μL ethanol stock into the 1,997.5μL of media  
 Remove the plates from the incubator   
 Check the cells under the microscope  
  Place inside the safety cabinet (do not spray in as this could kill the cells)  
 Open the plates and remove the old media from each well using a multi-
channel pipette  
 Dispose of the old media in the waste bottle.  
 Pipette 100μL of each concentration of media stock into the wells (as 
per template)  
o 3 wells at 25mM per plate  
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o  3 wells at 50mM per plate  
o 3 wells at 100mM per plate  
o 3 wells at 200mM per plate  
 Pipette 3 wells per plate with 100μL media and 1μL solvent, but no 
CLA, to act as a carrier control  
 Pipette 3 wells per plate with media only but no cells, and no CLA, to act as a 
background control   
 Return the lid to the well plates and label “0 hours”, “24 hours”, 
“48 hours” and “72 hours”  
 Incubate each plate for the desired time period   
 After the desired time, 
prior to removing the plate from the incubator, thaw the MTS reagent:  
o Remove from freezer  
o Spray into incubator (will take approximately 30min to defrost)  
 Remove plate from incubator and place in hood  
 Remove the plate lid  
 Add 20μL/100μL MTS reagent to each well, using a single pipette  
 Cover with lid and incubate again for 2 hours  
 Remove the plate from the incubator, and read using a plate reader at 490nm  
 
 
